11 February 2022>: Original PaperDayan Yang BCDEF , Qiqing Chen BCDF , Min Zhang BCDF , Lin Xie BCD , Yan Chen BCF , Tingting Zhong BCF , Fang Tian BC , Guiying Feng CF , Xiangxiang Jing ABEG* , Ling Lin ADF*
Ann Transplant 2022; 27:e933246
Figure 5 Evaluation for binding efficiency of PLGA+Fe3O4+PFP nanoparticles carried targeting CDDP with HNE1 cells (A) and HepG2 cells (B). Flow cytometry assay was conducted to examine targeting CDDP binding HNE1 or HepG2 cells. * P<0.05 vs targeting CDDP+PLGA+Fe3O4+PFP group. Microsoft Office PowerPoint/EXCELL 2010 (Redmond, WA, USA) was used to create images (n=6).